CliffBio
small molecule

AVAGE

TAZAROTENE

Loss of exclusivity—loss of exclusivity
CompanyAlmirall →See this company's full patent-cliff portfolio

Drug detail

Brand nameAVAGE
Active ingredientTAZAROTENE
Strength0.1%
Dosage formCREAM
RouteTOPICAL
ModalitySmall molecule
FDA approvalSeptember 2002
Marketing statusRX

More from Almirall

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

AVAGE patent cliff — loss of exclusivity — | CliffBio